27
3 Dimensions for Diabetes (3DFD) Khalida Ismail & Carol Gayle 8 th March 2016 King’s Fund, London

Khalida Ismail & Carol Gayle · Khalida Ismail & Carol Gayle 8 th March 2016. King’s Fund, London. Rochelle..... • female, late 20s, single parent • son age 4 years & daughter

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

  • 3 Dimensions for Diabetes (3DFD)

    Khalida Ismail & Carol Gayle8th March 2016

    King’s Fund, London

    http://hww-kingsweb/news/display.asp?itemID=25532http://hww-kingsweb/news/display.asp?itemID=25532http://www.guysandstthomas.nhs.uk/Home.aspxhttp://www.guysandstthomas.nhs.uk/Home.aspx

  • Rochelle.....

    • female, late 20s, single parent

    • son age 4 years & daughter age 18 months

    • type 1 diabetes in second pregnancy

    • HbA1c 108 mmol/mol• Undetected severe post

    partum depression

  • Depression and mortality in people with their first diabetic foot ulcer (n=253)

    Ismail K, Winkley K, Stahl D, Chalder T, Edmonds M. Diabetes Care 2007:30;1473-9Winkley K, Sallis H, Kariyawasam D, Leelarathra L, Chalder T, Edmonds M, Stahl D, Ismail K. Diabetologia 2012;155:303-10

    Funding: Wellcome Trust

  • Diabetes is associated with nearly every psychiatric disorder

    ICD-10 Chapter F categories Relative risk

    General popn/no psych disorder reference group

    Dementia 2.0

    Schizophrenia 3.0

    Substance use ~?

    Depression 2.0

    Eating disorders 2-3.0

    Chien et al Compr Psychiatry 2011; Anderson et al Diabetes Care 2000

  • Social problems

  • 3DFD: a blank canvas

  • Parallel versus integrated services

    Diabetes

    Social

    Mental Health

    Diabetes

    Social Mental Health

  • Active ingredients of 3DFD

    •diagnostic assessment•risk management•psychotropic •brief psychological

    treatments•family work

    • patient-led MDT meeting• increase self efficacy for

    diabetes • HbA1c• Patient reported outcomes

    • medication support• biomedical monitoring• diabetes education• technology• complications

    • debt management• housing support• occupational rehab• literacy• advocacy

    Social interventions

    Diabetes Management

    Liaison mental health

    services

    Patient

  • 3 Dimensions For Diabetes (3DFD) 1,2,3

    Social Interventions

    Diabetes management

    Liaison mental health

    services

    Patient

    Primary care Specialist care

    1 BMJ Best Diabetes Team Award 20142 Doherty et al International Journal of Psychiatry in Medicine 20163 NHS Regional Innovation Fund London 2010

  • Challenges and Opportunities • Defining the model? Whatever it was-it had to be simple• Full integration into diabetes teams, community and hospitals• MDT, Education and training

    De novo service

    • ‘luxury service’• Pathways – Improving Access to Psychological Services (IAPT)• Commissioners

    Organisational resistance

    • Cross sector steering group with Diabetes Modernisation Initiative

    • Evaluation, business case, dissemination & awards • Hospital charities and CCG funding• Commissioned service but needs scaling up

    Sustainability

  • 3DFD characteristicsYear 1

    Oct 2012-2013

    n=306

    Year 2

    Oct 2013-2014

    n=255

    Total

    Oct 2012-2014

    n=561

    Age, mean (SD) 47 (14.8) 50 (15.1) 48 (14.9)

    Gender n, (%) Male 121(39.4) 110 (43.3) 231 (41.2)

    Female 181 (60.6) 144 (56.7) 325 (58.8)

    Diagnosis n, (%) Type 1 89 (28.9) 60 (23.6) 149 (26.6)

    Type 2 218 (71.1) 194 (76.4) 412 (73.4)

    Ethnic group n, (%)

    Caucasian 76 (24.7) 81 (31.9) 157 (28.0)

    African/Caribbean 98 (31.9) 88 (34.6) 186 (33.2)

    Other 133 (43.2) 88 (33.5) 218 (38.8)

    HbA1cmean (SD)

    % (DCCT) 10.7 (1.9) 11.6 (2.1) 11.1 (2.0)

    mmol/mol (IFCC) 93 (10) 103 (11) 98 (10)

  • 3DFD characteristicsYear 1

    Oct 2012-2013

    n=306

    Year 2

    Oct 2013-2014

    n=255

    Total

    Oct 2012-2014

    n=561

    Age, mean (SD) 47 (14.8) 50 (15.1) 48 (14.9)

    Gender n, (%) Male 121(39.4) 110 (43.3) 231 (41.2)

    Female 181 (60.6) 144 (56.7) 325 (58.8)

    Diagnosis n, (%) Type 1 89 (28.9) 60 (23.6) 149 (26.6)

    Type 2 218 (71.1) 194 (76.4) 412 (73.4)

    Ethnic group n, (%)

    Caucasian 76 (24.7) 81 (31.9) 157 (28.0)

    African/Caribbean 98 (31.9) 88 (34.6) 186 (33.2)

    Other 133 (43.2) 88 (33.5) 218 (38.8)

    HbA1cmean (SD)

    % (DCCT) 10.7 (1.9) 11.6 (2.1) 11.1 (2.0)

    mmol/mol (IFCC) 93 (10) 103 (11) 98 (10)

  • 3DFD characteristicsYear 1

    Oct 2012-2013

    n=306

    Year 2

    Oct 2013-2014

    n=255

    Total

    Oct 2012-2014

    n=561

    Age, mean (SD) 47 (14.8) 50 (15.1) 48 (14.9)

    Gender n, (%) Male 121(39.4) 110 (43.3) 231 (41.2)

    Female 181 (60.6) 144 (56.7) 325 (58.8)

    Diagnosis n, (%) Type 1 89 (28.9) 60 (23.6) 149 (26.6)

    Type 2 218 (71.1) 194 (76.4) 412 (73.4)

    Ethnic group n, (%)

    Caucasian 76 (24.7) 81 (31.9) 157 (28.0)

    African/Caribbean 98 (31.9) 88 (34.6) 186 (33.2)

    Other 133 (43.2) 88 (33.5) 218 (38.8)

    HbA1cmean (SD)

    % (DCCT) 10.7 (1.9) 11.6 (2.1) 11.1 (2.0)

    mmol/mol (IFCC) 93 (10) 103 (11) 98 (10)

  • 3DFD characteristicsYear 1

    Oct 2012-2013

    n=306

    Year 2

    Oct 2013-2014

    n=255

    Total

    Oct 2012-2014

    n=561

    Age, mean (SD) 47 (14.8) 50 (15.1) 48 (14.9)

    Gender n, (%) Male 121(39.4) 110 (43.3) 231 (41.2)

    Female 181 (60.6) 144 (56.7) 325 (58.8)

    Diagnosis n, (%) Type 1 89 (28.9) 60 (23.6) 149 (26.6)

    Type 2 218 (71.1) 194 (76.4) 412 (73.4)

    Ethnic group n, (%)

    Caucasian 76 (24.7) 81 (31.9) 157 (28.0)

    African/Caribbean 98 (31.9) 88 (34.6) 186 (33.2)

    Other 133 (43.2) 88 (33.5) 218 (38.8)

    HbA1cmean (SD)

    % (DCCT) 10.7 (1.9) 11.6 (2.1) 11.1 (2.0)

    mmol/mol (IFCC) 93 (10) 103 (11) 98 (10)

  • 0

    5

    10

    15

    20

    Glicazide Gliptin Dapagliflozin Lamb/Swk DICT(n=472)

    3DFD (n=185)

    Impr

    ovem

    ent i

    n Hb

    A1c,

    mm

    ol/m

    ol

    Agents producing improved glycaemic control

    Improvement in HbA1c, mmol/mol

    Pre 3DFD Post 3DFD Change score p-value

    Mean (SD) DCCT % (n=185) 11.3 (2.1) 10 .0 (2.0) 1.5 (1.6)

  • Psychiatric morbidity

    0

    20

    40

    60

    80

    100

    120

    Nil Knowndiagnosis

    Newdiagnosis

    New relapse

    N

    Psychiatric Diagnosis

    Psychiatric diagnosis: new, known or relapse

    Chart1

    BPAD

    Psychosis

    Depression

    Anxiety Disorder

    Dementia

    Eating Disorder

    Alcohol dependence

    Adjustment Disorder

    Personality Disorder

    Learning disabililty

    Medically unexplained syndromes

    Mild psychological

    Number of patients with diagnosis

    Psychiatric diagnosis

    n

    Psychiatric diagnoses*

    3

    13

    87

    22

    5

    9

    15

    29

    11

    10

    8

    31

    Sheet1

    Number of patients with diagnosis

    BPAD3

    Psychosis13

    Depression87

    Anxiety Disorder22

    Dementia5

    Eating Disorder9

    Alcohol dependence15

    Adjustment Disorder29

    Personality Disorder11

    Learning disabililty10

    Medically unexplained syndromes8

    Mild psychological31

    243

  • Social Needs

  • Social Needs

    0

    5

    10

    15

    20

    25

  • Support worker assisting patient with type 2 diabetes with her housing situation

  • Quantitative outcomesPre 3DFD Post 3DFD Change score p-value

    Mean HbA1c, mmol/mol (SD)** 102 (22) 84 (22) -18 (17)

  • Main 3DFD outcomes - economic

    Pre 3DFD Post 3DFD Change score p-value

    No of admissions to A&E/previous year (n=119) 141 77 -64

  • Cost-benefit analysis

    Costs £94k/borough/year• 0.5WTE Consultant liaison psychiatrist• Community outreach worker• Admin support and infrastructure

    Savings £127k/borough/year (-on-year)• Short term: reduction in

    unscheduled care• Long term: reduction in developing

    diabetes complications

    3DFD net saving £33K/100 patients/borough/year recurrent≈ 35% return on investment per year

  • Patient testimonial

    My name is Rochelle, I am a single parent with two children. I had difficulties controlling my diabetes. I became very depressed. 3DFD has managed to help me to overcome my fears of dealing with diabetes. I now use my insulins better.....Rochelle:(T1DM) HbA1c 15.2 to 8.7%

  • Quality in Care Awards 2011

    BMJ Awards 2014Diabetes Team of the Year

    Mary McKinnon Lecture DUK 2015

    NHS Innovation Challenge Prize 2015

  • 3DFD

    Translation of research

    Cross sector

    integration

    Health inequalities

    Cost effective

    DisseminationOxford Surrey

    HillingdonEdinburgh

    Parsonage M, Fossey M, Tutty C. Liaison Psychiatry in the Modern NHS. Centre for mental Health, London. 2012, p35.

    3DFD

  • The Future

    • Scaling up– Identifying low vs high risk groups– Other long term physical conditions – Across the mental health trust

    • Health Foundation Scaling Up Bid 2016 – Shortlisted to final round– Results next week – Watch this space

  • Regional Innovation

    Fund

    http://www.guysandstthomas.nhs.uk/Home.aspxhttp://www.guysandstthomas.nhs.uk/Home.aspx

    3 Dimensions for Diabetes (3DFD)Rochelle.....Slide Number 3Diabetes is associated with nearly every psychiatric disorderSocial problems3DFD: a blank canvasParallel versus integrated servicesActive ingredients of 3DFD3 Dimensions For Diabetes (3DFD) 1,2,3�Challenges and Opportunities �Slide Number 11Slide Number 12Slide Number 13Slide Number 143DFD outcomes – HbA1c Psychiatric morbidity Social Needs Social NeedsSupport worker assisting patient with type 2 diabetes with her housing situationQuantitative outcomesMain 3DFD outcomes - economicCost-benefit analysisPatient testimonialQuality in Care Awards 2011Slide Number 25The Future Regional Innovation Fund